Wedbush Forecasts Nuvalent's Q3 Earnings (NASDAQ:NUVL)

Key Points

• Wedbush revised down its Q3 2025 earnings estimate for Nuvalent to ($1.31) per share, down from the previous estimate of ($1.21), while maintaining an "Outperform" rating and a target price of $115.00.
• Nuvalent's recent quarterly earnings report showed a loss of ($1.31) per share, missing the consensus estimate by ($0.04), and reflecting a deterioration compared to the previous year's loss of ($0.88) EPS.
• A significant insider sale occurred on August 7th, with insider Henry E. Pelish selling 5,500 shares at an average price of $74.85, marking an 8.28% decrease in their ownership.

Nuvalent, Inc. (NASDAQ:NUVL - Free Report) - Research analysts at Wedbush dropped their Q3 2025 earnings estimates for shares of Nuvalent in a research report issued on Thursday, August 7th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.31) per share for the quarter, down from their prior estimate of ($1.21). Wedbush currently has a "Outperform" rating and a $115.00 target price on the stock. The consensus estimate for Nuvalent's current full-year earnings is ($3.86) per share. Wedbush also issued estimates for Nuvalent's Q4 2025 earnings at ($1.38) EPS, FY2026 earnings at ($6.17) EPS, FY2027 earnings at ($5.62) EPS and FY2028 earnings at ($1.78) EPS.

Nuvalent (NASDAQ:NUVL - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.04). During the same quarter in the prior year, the company posted ($0.88) EPS.

Several other research firms also recently weighed in on NUVL. Robert W. Baird upped their price objective on shares of Nuvalent from $105.00 to $112.00 and gave the stock an "outperform" rating in a report on Wednesday, June 25th. HC Wainwright restated a "buy" rating and set a $130.00 price objective (up previously from $110.00) on shares of Nuvalent in a report on Tuesday, June 24th. The Goldman Sachs Group upgraded shares of Nuvalent to a "strong-buy" rating in a report on Monday, June 30th. Finally, Leerink Partners upped their price objective on shares of Nuvalent from $125.00 to $140.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $119.60.

Nuvalent Stock Up 2.7%

NASDAQ:NUVL opened at $74.11 on Monday. The company has a fifty day moving average of $78.99 and a 200-day moving average of $76.12. The firm has a market capitalization of $5.32 billion, a P/E ratio of -15.12 and a beta of 1.30. Nuvalent has a twelve month low of $55.53 and a twelve month high of $113.51.

Insider Buying and Selling at Nuvalent

In other Nuvalent news, insider Henry E. Pelish sold 5,500 shares of the company's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $74.85, for a total transaction of $411,675.00. Following the sale, the insider directly owned 60,956 shares of the company's stock, valued at $4,562,556.60. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Alexandra Balcom sold 14,700 shares of the company's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $85.10, for a total transaction of $1,250,970.00. Following the sale, the chief financial officer directly owned 61,734 shares in the company, valued at approximately $5,253,563.40. This trade represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 91,145 shares of company stock valued at $7,419,532 over the last three months. 10.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nuvalent

Several institutional investors have recently added to or reduced their stakes in the business. CWM LLC lifted its holdings in shares of Nuvalent by 588.5% in the first quarter. CWM LLC now owns 420 shares of the company's stock worth $30,000 after buying an additional 359 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Nuvalent in the first quarter worth about $38,000. Quarry LP purchased a new stake in shares of Nuvalent in the fourth quarter worth about $39,000. Covestor Ltd lifted its holdings in shares of Nuvalent by 705.7% in the first quarter. Covestor Ltd now owns 983 shares of the company's stock worth $70,000 after buying an additional 861 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Nuvalent by 9,230.8% in the second quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company's stock worth $93,000 after buying an additional 1,200 shares in the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.